Pharmacotherapeutic management of actinic keratosis: Focus on newer topical agents

American Journal of Clinical Dermatology

Volumn 14, Issue 4, 2013, Pages 273-277

  Samrao, Aman ^a   Cockerell, Clay J ^b,c  

^a Division of Dermatology   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Dermpath Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIC ACID; CORTICOSTEROID; DICLOFENAC; FLUOROURACIL; FLUOROURACIL PLUS SALICYLIC ACID; IMIQUIMOD; INGENOL MEBUTATE; LAS 41005; PIROXICAM; PLACEBO; RESIQUIMOD; SALICYLIC ACID; TOPICAL AGENT; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ANGIONEUROTIC EDEMA; CLINICAL SKIN REACTION; CONTACT SENSITIZATION; CONTROLLED CLINICAL TRIAL (TOPIC); CREAM; CRYOTHERAPY; DERMATITIS; DESQUAMATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; DRY EYE; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; GEL; HUMAN; LACRIMATION; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN BURNING SENSATION; SKIN DISCOLORATION; SKIN EROSION; SKIN IRRITATION; SKIN PAIN; SKIN PRURITUS; SKIN SCABBING; SKIN SCALING; SKIN SCAR; SKIN ULCER; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; XEROSIS;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CRYOTHERAPY; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KERATOSIS, ACTINIC; MALE; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880879996     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0023-y     Document Type: Review

References (20)

1. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89(5):241-50.
2. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: commonly used field-directed and lesion-directed therapies. Cutis. 2012;89(6):294-301.
3. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335-9. (Pubitemid 44328971)
4. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(suppl 2):34-40. (Pubitemid 350179628)
5. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil 0.5% cream for the treatment of actinic keratosis. Arch Dermatol. 2009;145:203-5.
6. Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813-6. (Pubitemid 38917849)
7. Stockfleth E, Sterry W, Carey-Yard M, et al. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157(suppl 2):41-6. (Pubitemid 350179629)
8. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582-90.
9. Foley P, Merlin K, Cumming S, Campbell J, et al. A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol. 2011;10(12):1432-8.
10. Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11:195-201.
11. Martin GM, Stockfleth E. Diclofenac sodium 3% gel for the management of actinic keratosis: 10 + years of cumulative evidence of efficacy and safety. J Drugs Dermatol. 2012;11(5):600-8.
12. de Berker D, McGregor JM, Hughes BR. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses [published correction in Br J Dermatol. 2008;158:873]. Br J Dermatol. 2007;156:222-30. (Pubitemid 46098882)
13. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol. 2009;34(1):33-5.
14. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156-9.
15. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833-9. (Pubitemid 38500622)
16. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16-22.
17. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101-8.
18. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205-10. (Pubitemid 351874499)
19. Campione E, Diluvio L, Paternò EJ, et al. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11:45-50.
20. Huyke C, Reuter J, Rödig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7(2):128-33.